We are live on ! Find out more
GBT

Global Blood Therapeutics, Inc.
GBT

Delisted

GBT was delisted on the 4th of October, 2022.

Back to rankings

2 hedge funds and large institutions have $42.1K invested in Global Blood Therapeutics, Inc. in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 239 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 247 → 2 (-245)

100% less funds holding in top 10

Funds holding in top 10: 21 → 0 (-21)

100% less capital invested

Capital invested by funds: $4.73B → $42.1K (-$4.73B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 239

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-245
Holders Change %
-99.19%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-21
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
239
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$428M
2
BlackRock
BlackRock
New York
-$323M
3
BBA
Baker Bros. Advisors
New York
-$254M
4
PCM
Pentwater Capital Management
Florida
-$218M
5
State Street
State Street
Massachusetts
-$162M
Name Holding Trade Value Shares
Change 		Change in
Stake
VI
26
Versor Investments
New York
– -$43.7M -641,904 Closed
Man Group
27
Man Group
United Kingdom
– -$43.5M -639,097 Closed
AA
28
AQR Arbitrage
Connecticut
– -$41.3M -605,777 Closed
Assenagon Asset Management
29
Assenagon Asset Management
Luxembourg
– -$40.2M -590,153 Closed
N
30
Nuveen
North Carolina
– -$40.1M -589,525 Closed
Northern Trust
31
Northern Trust
Illinois
– -$39.7M -583,069 Closed
NAM
32
Nexpoint Asset Management
Texas
– -$39.3M -577,150 Closed
T. Rowe Price Associates
33
T. Rowe Price Associates
Maryland
– -$38.9M -571,115 Closed
Millennium Management
34
Millennium Management
New York
– -$37M -543,632 Closed
Charles Schwab
35
Charles Schwab
California
– -$32.7M -480,794 Closed
Fidelity Investments
36
Fidelity Investments
Massachusetts
– -$31.8M -467,573 Closed
Morgan Stanley
37
Morgan Stanley
New York
– -$31.6M -464,630 Closed
FCM
38
Farallon Capital Management
California
– -$30.6M -450,000 Closed
GF
39
Gabelli Funds
New York
– -$29.4M -432,378 Closed
WCMNY
40
Westchester Capital Management (New York)
New York
– -$27.6M -405,863 Closed
Allianz Asset Management
41
Allianz Asset Management
Germany
– -$27.3M -401,197 Closed
CC
42
Carlson Capital
Texas
– -$27.2M -400,000 Closed
AllianceBernstein
43
AllianceBernstein
Tennessee
– -$27.2M -399,290 Closed
American Century Companies
44
American Century Companies
Missouri
– -$26.6M -391,051 Closed
TS
45
Twin Securities
New York
– -$25.7M -376,669 Closed
Public Sector Pension Investment Board (PSP Investments)
46
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
– -$25.3M -371,400 Closed
CS
47
Candriam SCA
Luxembourg
– -$24.6M -360,956 Closed
AIM
48
Alerce Investment Management
Illinois
– -$24.3M -356,270 Closed
FTCM
49
First Trust Capital Management
Illinois
– -$23.8M -349,165 Closed
DTC
50
Deep Track Capital
Connecticut
– -$22.2M -326,600 Closed
1
2
3 4 5

GBT Hedge Fund Activity: Q4 2022 in Review

2 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q4 2022, worth a combined $42.1K — down 100% from $4.73B a quarter earlier.

Sellers outnumbered buyers: 239 funds closed out of GBT and 0 opened new positions — a net loss of 239 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $428M sold.

  • 2 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q4 2022, down from 247 in Q3 2022.
  • Funds reported $42.1K of Global Blood Therapeutics, Inc. stock for Q4 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Global Blood Therapeutics, Inc. positions in Q4 2022 and 239 closed out, a net change of -239 holders.
  • The largest Global Blood Therapeutics, Inc. seller in Q4 2022 was Vanguard Group, an estimated $428M sold.

Based on aggregated 13F filings for Q4 2022.